157 related articles for article (PubMed ID: 10557040)
21. Detection of minimal residual disease in B-lymphoproliferative disorders: a three step SSCP-PCR method.
Miglino M; Grasso R; Pietrasanta D; Palmisano GL; Berisso G; Clavio M; Pierri I; Santini G; Canepa L; Gobbi M
J Exp Clin Cancer Res; 2001 Mar; 20(1):95-101. PubMed ID: 11370837
[TBL] [Abstract][Full Text] [Related]
22. Detection of minimal residual disease.
Gribben J; Nadler L
Cancer Treat Res; 1995; 76():249-70. PubMed ID: 7577338
[No Abstract] [Full Text] [Related]
23. Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation.
Miglino M; Santini G; Grasso R; Pietrasanta D; Clavio M; Pierri I; Canepa L; Nati S; Ballerini F; Varaldo R; Palmisano G; Gobbi M
Haematologica; 2001 Jul; 86(7):706-14. PubMed ID: 11454525
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes.
Corradini P; Ladetto M; Zallio F; Astolfi M; Rizzo E; Sametti S; Cuttica A; Rosato R; Farina L; Boccadoro M; Benedetti F; Pileri A; Tarella C
J Clin Oncol; 2004 Apr; 22(8):1460-8. PubMed ID: 15084619
[TBL] [Abstract][Full Text] [Related]
25. Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: a review.
Sharp JG; Mann SL; Murphy B; Weekes C
J Hematother; 1995 Jun; 4(3):141-8. PubMed ID: 7551913
[TBL] [Abstract][Full Text] [Related]
26. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
27. Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers.
Sabesan V; Cairo MS; Lones MA; Perkins SL; Morris E; Sposto R; Van De Ven C; Shiramizu B
J Pediatr Hematol Oncol; 2003 Feb; 25(2):109-13. PubMed ID: 12571460
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications of molecular and cytogenetic studies of non-Hodgkin's lymphomas.
Hammond DW; Hancock BW; Goyns MH
Cancer Treat Rev; 1998 Apr; 24(2):157-63. PubMed ID: 9728424
[No Abstract] [Full Text] [Related]
29. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P
Semin Oncol; 2002 Feb; 29(1 Suppl 2):48-55. PubMed ID: 11842389
[TBL] [Abstract][Full Text] [Related]
30. Molecular basis for stem cell transplantation in indolent lymphomas.
Gribben JG
Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S37-45. PubMed ID: 9672773
[TBL] [Abstract][Full Text] [Related]
31. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
32. Detection and treatment of minimal residual disease in high-risk neuroblastoma.
Reynolds CP
Pediatr Transplant; 2004 Jun; 8 Suppl 5():56-66. PubMed ID: 15125707
[TBL] [Abstract][Full Text] [Related]
33. Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications, and emerging therapeutic consequences.
Köstler WJ; Brodowicz T; Hejna M; Wiltschke C; Zielinski CC
Cancer Detect Prev; 2000; 24(4):376-403. PubMed ID: 11059569
[TBL] [Abstract][Full Text] [Related]
34. Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment.
Grimaldi D; Genuardi E; Ferrante M; Ferrero S; Ladetto M
Curr Treat Options Oncol; 2018 Nov; 19(12):71. PubMed ID: 30402764
[TBL] [Abstract][Full Text] [Related]
35. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
[TBL] [Abstract][Full Text] [Related]
36. Real-time quantitative PCR using hairpin-shaped clone-specific primers for minimal residual disease assessment in an animal model of human non-Hodgkin lymphoma.
Gentilini F; Turba ME; Calzolari C; Cinotti S; Forni M; Zannoni A
Mol Cell Probes; 2010 Feb; 24(1):6-14. PubMed ID: 19651205
[TBL] [Abstract][Full Text] [Related]
37. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
38. [Detection of minimal residual disease in children leukemia patients by using PCR - review].
He YY; Ye TZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):652-6. PubMed ID: 17605887
[TBL] [Abstract][Full Text] [Related]
39. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
Møller MB; Nielsen O; Pedersen NT
Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
[TBL] [Abstract][Full Text] [Related]
40. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
